CombiMatrix Announces Publication of Clinical Validation Study of the HemeScan Array for Chronic Lymphocytic Leukemia
Tuesday August 12, 6:00 am ET
MUKILTEO, Wash., Aug. 12, 2008 (PRIME NEWSWIRE) -- CombiMatrix Corporation (NasdaqGM:CBMX - News) announced today that a retrospective, clinical validation study of its test for Chronic Lymphocytic Leukemia (CLL) is to be published in the September issue of the Journal of Molecular Diagnostics (J Mol Diagn 2008, 10:442-451). This publication augments an earlier publication in the Expert Opinions in Molecular Diagnostics ((2008) 2(6): 1-10). Dr. Shelly Gunn, M.D., Ph.D. Medical Director of CombiMatrix Molecular Diagnostics (CMDX), was the lead author of both publications.
The subject of both publications is the clinical evaluation and prognosis of CLL patients with CombiMatrix's HemeScan(tm) test, compared to conventional testing. The conclusions indicate that the HemeScan test is a superior test for such evaluation and management of individual patients.
Dr. Shelly Gunn, M.D., Ph.D. Medical Director of CMDX, noted, ``These studies we have now published were retrospective in nature. Additionally, more recent data with the HemeScan test on currently diagnosed patients have demonstrated even greater superiority of the HemeScan test relative to traditional testing.'' Dr. Gunn further added, ``These data will be published soon, and we hope it will provide enough clinical evidence to help drive the adoption of the HemeScan test as a new standard for the evaluation and management of CLL patients.
Dr. Ryan Robetorye, M.D., Ph.D., Director of the Molecular Diagnostics and Clinical Genomics Laboratories at The University of Texas Health Science Center at San Antonio noted, ``As a hematopathologist I am acutely aware of the limitations involved in applying traditional methodologies for the analysis of heterogeneous and complex malignancies and then attempting to use this limited information for subsequent patient management. CombiMatrix's HemeScan test has demonstrated its superiority to conventional testing methods and has benefited many patients. I firmly believe that the suite of oncology tests offered by CombiMatrix will set a new standard for the analysis and risk-stratification of human malignancies. This will ultimately allow the most appropriate therapeutic regimens to be provided to patients.''
ABOUT COMBIMATRIX CORPORATION
We are a diversified biotechnology business, through the development of proprietary technologies, products and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology research, defense and homeland security markets, as well as other potential markets where our products and services could be utilized. The technologies we have developed include a platform technology to rapidly produce oligonucleotide arrays for use in identifying and determining the roles of genes, gene mutations and proteins. We make the arrays using our patented in situ electrochemical synthesis process, which provides the ability to easily change array content to stay current with new developments and to meet the evolving needs of our customers. This technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology. We have also developed the capabilities of producing arrays that utilize bacterial artificial chromosomes on our arrays, also enabling genetic analysis. Other technologies include proprietary molecular synthesis and screening methods for the discovery of potential new drugs. CombiMatrix Molecular Diagnostics, Inc. (``CMDX''), our wholly owned subsidiary located in Irvine, California, has developed capabilities of producing arrays that utilize bacterial artificial chromosomes, which also enable genetic analysis. CMDX functions primarily as a diagnostics reference laboratory.
Additional information about CombiMatrix Corporation is available at combimatrix.com or by calling 1-800-985-CBMX (2269). Additional information about CMDX is available at cmdiagnostics.com or by calling 1-800-710-0624 |
